GILOTRIF (afatinib)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 substitution mutation

Patients must meet the following criteria for the indication(s) above:

  • All patients must undergo genetic testing to confirm EGFR status
  • Gene mutations must be documented by FDA approved genetic testing

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All uses not listed in the approved indications

Recommended Dosing

  • 40 mg orally once daily until disease progression or intolerable side effects
  • Drug should be taken 1 hour before or 2 hours after meals.

Approval:

Six months


 

Last review date: January 1, 2014

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone